Kodiak Sciences Inc. (KOD) Balance Sheet

The sequential decline in assets and equity is driven by persistent operating losses with no revenue, as evidenced by the widening accumulated deficit from -$1.2B to -$1.7B over the period. The equity base has contracted by over 74% from its peak, suggesting that the company is consuming capital at an unsustainable rate. This trajectory implies that without additional financing or a successful clinical outcome, the balance sheet may become insufficient to support ongoing operations.

The D/E ratio's increase is primarily a function of equity depletion, as total debt actually declined by $23M over the period. However, the 2026Q1 spike to 1.39 with debt of $156M suggests a temporary drawdown, possibly for working capital needs, which was partially repaid by 2026Q2. This pattern indicates that the company may be using debt as a bridge to fund operations, but the lack of revenue raises concerns about its ability to service this debt over the long term.

The steady decline in PPE suggests that the company is not investing in fixed assets, consistent with its focus on R&D rather than manufacturing. Goodwill remains zero, indicating no acquisition-related intangibles, which reduces impairment risk. The shrinking asset base, however, limits the collateral available for future borrowing, potentially constraining financing options.

The equity erosion is driven by cumulative net losses, which have outpaced any capital raises, as evidenced by the widening deficit. Stock-based compensation, which totaled $11.6M in 2026Q2, adds to dilution but does not offset the cash burn. The equity base is now thin relative to liabilities, suggesting that the company may need to raise capital soon, potentially at dilutive terms.

The current ratio remains above 1, but the rapid decline in cash and equivalents suggests that the company has less than two years of runway at the current burn rate, which averaged around $50M per quarter. The liquidity buffer is being consumed by R&D and SBC, with no revenue to replenish it. This trend implies that the company may face a liquidity crunch if it cannot secure additional financing or achieve a value-creating milestone.